REBECCA TURNER: Open Payments
NPI 1053401588 · SHENANDOAH, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$772 in 28 payments from 12 companies in 2025. Trend: 2023 $1,199 · 2024 $518 · 2025 $772
Food & beverage: $772
| Company | Payments | Amount |
|---|---|---|
| Sumitomo Pharma America, Inc. | 9 | $193 |
| Janssen Biotech, Inc. | 3 | $192 |
| Ferring Pharmaceuticals Inc. | 4 | $111 |
| Endo USA, Inc. | 2 | $47 |
| Teleflex LLC | 1 | $36 |
| Antares Pharma, Inc. | 2 | $36 |
| Myriad Genetic Laboratories, Inc. | 1 | $34 |
| Dendreon Pharmaceuticals LLC | 1 | $33 |
| ABBVIE INC. | 2 | $31 |
| Novartis Pharmaceuticals Corporation | 1 | $27 |
Products named: GEMTESA, RYBREVANT, ADSTILADRIN, ERLEADA, UROLIFT, XYOSTED, PROLARIS, PROVENGE.
Industry payments across TX — which companies pay providers there.
